Lattice Biologics Ltd. (LBLTF)
Lattice Biologics Ltd. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Belgrade, MT, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $16,545. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -60.2%. Its beta of 1.14 implies it has historically moved more than the broad market.
Lattice Biologics Ltd. is a biotechnology firm focused on developing, manufacturing, and commercializing biological products designed for bone regeneration. These solutions are utilized globally across dental, spinal, and general orthopedic indications. The company's innovative offerings include novel amniotic fluid-based therapies such as AmnioBoost and AmnioBlast. In addition, their product line features a broad range of allografts, encompassing traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix varieties. These versatile products serve numerous critical medical applications, from enhancing spinal fusion and aiding breast reconstruction post-mastectomy to promoting bone regeneration in foot and ankle surgeries and fostering skull healing after neurosurgery. They also play a role in improving wound repair for burn victims, facilitating hernia repair, addressing subchondral bone defects in knee and other joint surgeries, and supporting various sports medicine procedures, including anterior and posterior cruciate ligament repairs. The company's headquarters are located in Belgrade, Montana.
Lattice Biologics Ltd. is most often compared with the following Healthcare names: